The independent bid committee of Vigmed continues to recommend the shareholders of Vigmed to accept the offer by Greiner Bio-One
Yesterday on 21 March 2017, the independent bid committee (the “Bid committee”)[1], appointed by the Board of Directors of Vigmed Holding AB (“Vigmed”) following the public offer by Greiner Bio-One GmbH on 27 February 2017 (the “Offer”), was informed of an announcement made by Beijing Topraise Medical Technology . The Bid Committee has not received any other information pertaining to the potential loan offer than set out in the announcement.